PDF(Pubmed)
Abstract：
Breast cancer has historically been a disease for which immunotherapy was largely unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with chemotherapy for the treatment of advanced/metastatic triple-negative breast cancer (TNBC) has demonstrated efficacy, including longer progression-free survival and increased overall survival in subsets of patients. Based on clinical benefit in randomized trials, ICIs in combination with chemotherapy for the treatment of some patients with advanced/metastatic TNBC have been approved by the United States (US) Food and Drug Administration (FDA), expanding options for patients. Ongoing questions remain, however, about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based selection of patients for treatment, the optimal strategy for immunotherapy treatment in earlier stage disease, and potential use in histological subtypes other than TNBC. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew upon the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for breast cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence-based and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with breast cancer.
摘要：
乳腺癌历来是一种免疫疗法在很大程度上不可用的疾病。最近,使用免疫检查点抑制剂（ICIs）联合化疗治疗晚期/转移性三阴性乳腺癌（TNBC）已证明有效，包括延长无进展生存期和增加患者亚组的总生存期。根据随机试验的临床获益，ICIs与化疗联合用于治疗一些晚期/转移性TNBC患者已获得美国（US）食品和药物管理局（FDA）的批准，扩大患者的选择范围。持续的问题仍然存在，然而,关于免疫疗法的最佳化疗骨干，适当的基于生物标志物的患者治疗选择，早期疾病免疫治疗的最佳策略，以及在TNBC以外的组织学亚型中的潜在用途。就这些和其他重要问题向肿瘤学界提供指导，癌症免疫治疗学会(SITC)召集了一个多学科专家小组,以制定临床实践指南(CPG).专家小组根据已发表的文献及其临床经验，就乳腺癌免疫治疗的这些重要方面为医疗保健专业人员提供建议。包括诊断测试，治疗计划,免疫相关不良事件（IRAE），和患者生活质量（QOL）的考虑。本CPG中基于证据和基于共识的建议旨在为治疗乳腺癌患者的癌症护理提供者提供指导。
